Fig. 4: Kaplan-Meier plots of new genomic risk factors in high-risk smoldering myeloma under treatment. | Blood Cancer Journal

Fig. 4: Kaplan-Meier plots of new genomic risk factors in high-risk smoldering myeloma under treatment.

From: The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

Fig. 4

Biochemical progression-free survival curves of the 44 high-risk SMM cases were plotted based on the presence (red) or absence (black) of different alterations at baseline. The 13 ultrahigh-risk patients were not considered here. (A) KRAS mutations; (B) NRAS mutations; (C) concurrent FGFR3 mutation and t(4;14). The number of patients for each category is shown in brackets. bPFS biochemical progression-free survival SV structural variant, WT wild type.

Back to article page